Superior Genomics, Inc.

NORWAY, MI · CIK 0002148532 · Biotech

Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$508K
1 Form D · Aug 2026
2 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$507,500
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1834DOUBLE LUCKY BIOPHARM, LTD——
1835Prometheus Capital Partners LLC—$50K
1836Alzamend Neuro, Inc.—$232K
1837Superior Genomics, Inc.—$508K
1838CONCEPTION HOLDINGS, INC.—$50K
1839TRANSLATIONAL SCIENCES INC.——
1840Entelo, Inc.—$4.9M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • John FreshleyDirector
  • David Van HollaDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.